The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of mirabegron, having considered evidence on the nature of overactive bladder (OAB) and the value placed on ...

Review the side-effects of Mirabegron as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

MILAN, Italy — The safety and adverse-effect profile of mirabegron (Myrbetriq, Astellas Pharma) for overactive bladder compares favorably with placebo and tolterodine, new research shows. Two separate ...

CHICAGO, May 5, 2019 /PRNewswire/ -- Astellas Pharma Inc. today announced results from the Phase 4, 12-week PLUS trial, the first large-scale, randomized trial in North America and Europe evaluating ...

Background: Antimuscarinic agents are currently the predominant treatment option for the clinical management of the symptoms of overactive bladder (OAB). However, low rates of persistence with these ...

Zydus is introducing mirabegron extended-release tablets, 25 mg, which is the generic of Myrbetriq. Zydus is among the first suppliers to launch the generic version of mirabegron extended-release ...

heart chambers atrial fibrillation Researchers on the BEAT-HF trial have concluded that, in patients with chronic heart failure, mirabergron failed to improve left ventricular ejection fraction.

AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) announces the launch of ...

https://www.thehindubusinessline.com/companies/lupin-clears-patent-hurdle-with-astellas-pharma-keeps-mirabegron-sales-in-us/article70613710.ece Copy Lupin said on ...